^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + GSK2636771 (PI3Kβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1085P-Ph I/II study of PI3K-ß inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Published date:
09/13/2021
Excerpt:
...we conducted a phase I/II study (NCT01458067) of PI3Kβi + P in pts w/ PTEN loss, including PD-1 refractory MM....PRs were achieved in 3 pts (12%) and clinical benefit rate (CR/PR/SD) was 52%, including 3 pts with >1 yr on therapy. Median PFS was 3.4 mos (95% CI: 2.5-6.0)….G771 (200 mg PO QD) + P was tolerable, but response was modest.
Trial ID:
